Skip to main content
Premium Trial:

Request an Annual Quote

Nastech Licenses RNAi Patents from Carnegie Institution

NEW YORK, Feb. 2 (GenomeWeb News) - Nastech Pharmaceutical Company has licensed RNA interference patents and patent applications from the Carnegie Institution of Washington, the company said today.

 

The worldwide, non-exclusive license covers small interfering RNA technology, including U.S. Patent 6,506,559 B1. Nastech plans to use the technology in tight junction research and to develop therapeutics.

 

Nastech, based in Bothell, Wash., is developing methods to deliver drugs through the nose.

 

The Scan

Rare Genetic Disease Partnership

A public-private partnership plans to speed the development of gene therapies for rare genetic diseases, Stat News writes.

Approval Sought for Alzheimer's Drug

The Wall Street Journal reports Eli Lilly has initiated a rolling submission to the US Food and Drug Administration to seek approval for its drug to treat Alzheimer's disease.

DNA Barcoding Paper Retracted

Science reports that a 2014 DNA barcoding paper was retracted after a co-author brought up data validity concerns.

Nature Papers Present Genomic Analysis of Bronze Age Mummies, Approach to Study Host-Pathogen Interactions

In Nature this week: analysis finds Tarim mummies had local genetic origin, and more.